文献速递浆细胞疾病

多发性骨髓瘤患者未持续可测量残留病阴性的预测因素

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
PubMed 文献 · Blood · 2024-01-01

该研究分析FORTE试验(NCT02203643)中306例MRD阴性多发性骨髓瘤患者,中位随访50.4个月,185例(60%)维持MRD阴性且无进展,118例(39%)丧失MRD阴性。Amp1q、≥2个高危细胞遗传学异常、基线循环肿瘤细胞高及巩固后达MRD阴性均与未持续MRD阴性风险升高相关;维持治疗前2年卡非佐米-来那度胺较来那度胺单药降低该风险。

要点

  • MRD阴性患者中60%维持阴性且无进展,39%丧失MRD阴性。
  • Amp1q、≥2个高危细胞遗传学异常、基线高循环肿瘤细胞与未持续MRD阴性相关。
  • 维持治疗前2年卡非佐米-来那度胺较来那度胺单药降低未持续MRD阴性风险。

核心结论

  • Amp1q、≥2个高危细胞遗传学异常、基线高循环肿瘤细胞及巩固后达MRD阴性是多发性骨髓瘤患者未持续MRD阴性的预测因素。
  • 维持治疗前2年接受卡非佐米-来那度胺的患者较来那度胺单药者未持续MRD阴性风险更低。

研究设计与样本

  • 分析FORTE试验(NCT02203643)入组的多发性骨髓瘤患者。
  • 采用多参数流式细胞术检测MRD,灵敏度10⁻⁵,于维持治疗前及之后每6个月进行。
  • 共分析474例MRD阴性患者中的306例(65%)。

主要发现

  • 自MRD阴性起中位随访50.4个月,306例中185例(60%)仍MRD阴性且无进展,118例(39%)丧失MRD阴性,3例(1%)无进展死亡。
  • Amp1q vs 正常:4年累积发生率63% vs 34%;≥2个合并高危细胞遗传学异常 vs 0个:59% vs 33%。
  • 基线循环肿瘤细胞高 vs 低:4年累积发生率62% vs 32%;巩固后 vs 巩固前达MRD阴性:4年累积发生率46% vs 35%。
  • 维持治疗前2年卡非佐米-来那度胺 vs 来那度胺单药:未持续MRD阴性4年累积发生率20% vs 33%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prognostic impact of achieving and in particular maintaining measurable residual disease (MRD) negativity in multiple myeloma is now established; therefore, identifying among MRD-negative patients the ones at higher risk of losing MRD negativity is of importance. We analyzed predictors of unsustained MRD negativity in patients enrolled in the FORTE trial (NCT02203643). MRD was performed by multiparameter flow cytometry (sensitivity of 10-5) at premaintenance and every 6 months thereafter. The cumulative incidence (CI) of MRD resurgence and/or progression was analyzed in MRD-negative patients. A total of 306 of 474 (65%) MRD-negative patients were analyzed. After a median follow-up of 50.4 months from MRD negativity, 185 of 306 (60%) patients were still MRD negative and progression free, 118 (39%) lost their MRD-negative status, and 3 patients (1%) died without progression. Amp1q vs normal (4-year CI, 63% vs 34), ≥2 concomitant high-risk cytogenetic abnormalities vs 0 (4-year CI, 59% vs 33%), circulating tumor cells at baseline (high vs low at 4-year CI, 62% vs 32%), and time-to-reach MRD negativity postconsolidation vs preconsolidation (4-year CI, 46% vs 35%) were associated with a higher risk of unsustained MRD negativity in a multivariate Fine-Gray model. During the first 2 years of maintenance, patients receiving carfilzomib-lenalidomide vs lenalidomide alone had a lower risk of unsustained MRD negativity (4-year CI, 20% vs 33%).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. D'Agostino M, Bertuglia G, Rota-Scalabrini D, et al. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. Blood. 2024. PMID: 38048557. doi:10.1182/blood.2023022080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。